Schonfeld Strategic Advisors LLC decreased its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 79.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 71,400 shares of the company's stock after selling 283,295 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Roivant Sciences were worth $845,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Roivant Sciences by 0.3% in the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. raised its stake in Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after acquiring an additional 2,404,232 shares during the last quarter. Two Seas Capital LP lifted its position in Roivant Sciences by 4.6% during the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after acquiring an additional 442,914 shares during the period. Invesco Ltd. grew its stake in Roivant Sciences by 49.7% during the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Roivant Sciences by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock valued at $91,968,000 after purchasing an additional 26,727 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Trading Down 2.1%
ROIV traded down $0.23 on Tuesday, hitting $10.76. 4,466,878 shares of the company's stock were exchanged, compared to its average volume of 5,882,916. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The firm has a 50-day moving average price of $10.49 and a 200-day moving average price of $11.10. The stock has a market cap of $7.68 billion, a price-to-earnings ratio of -71.73 and a beta of 1.23.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on ROIV shares. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st.
View Our Latest Report on Roivant Sciences
Insider Activity at Roivant Sciences
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the transaction, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at $1,702,843.52. This trade represents a 58.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,669,500 shares of company stock valued at $18,064,847 over the last three months. 7.90% of the stock is owned by corporate insiders.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
